Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-5: Odronextamab + lenalidomide vs rituximab + lenalidomide in relapsed/refractory follicular or marginal zone lymphoma
jRCT2021260033Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of odronextamab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) for odronextamab in combination with lenalidomide (Part 1), Incidence of treatment-emergent adverse events (TEAEs) for odronextamab in combination with lenalidomide (Part 1) and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2021260033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260033.